BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline ATTR-CM. An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM. BridgeBio and acoramidis’ European licensing partner, Bayer, presented data on the drug’s potential in rare cardiac disease, ATTR-CM at the ESC’s 2026 Heart Failure congress. Credit: Komsan Loonprom / Shutterstock.com. BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax (tafamidis), as the former company looks to continue establishing market share in the transthyretin amyloid cardiomyopathy (ATTR-CM)…

Source: Clinical Trials Arena